全球运甲状腺素蛋白淀粉样变性治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

全球转甲状腺素蛋白淀粉样变性治疗市场的需求预计将从 2022 年的 69.4 亿美元达到 2030 年近 147.3 亿美元的市场规模，2023-2030 年研究期间复合年增长率为 8.72%。

运甲状腺素蛋白淀粉样变性治疗可减少淀粉样变性并限制淀粉样蛋白的产生。运甲状腺素蛋白淀粉样变性是一种罕见且危及生命的疾病。这种疾病会影响一个人的多个器官，症状包括食慾不振、腹泻、椎管狭窄、便秘等。甲状腺素运载蛋白淀粉样变性的发生有多种原因，例如遗传因素、骨髓疾病，甚至是其他一些潜在疾病。

市场动态：

支持性报销计划的存在和不断增长的非裔美国人人口推动了转甲状腺素蛋白淀粉样变性治疗市场的发展。此外，疾病患病率的增加和对治疗选择的需求的增加预计将很快推动市场的增长。此外，新疗法的推出预计将促进转甲状腺素蛋白淀粉样变性治疗市场的增长。此外，推动全球转甲状腺素蛋白淀粉样变性治疗市场的主要因素是认识的提高、诊断程序的进步、医疗保健服务的改善、发展中国家经济的快速增长以及研发活动的增加。然而，转甲状腺素蛋白淀粉样变性治疗的认知度低和成本高可能会阻碍市场增长。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球转甲状腺素蛋白淀粉样变性治疗市场的各个细分市场进行了包容性评估。转甲状腺素蛋白淀粉样变性治疗行业的增长和趋势为本研究提供了整体方法。

区域分析：

本节介绍区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲对转甲状腺素蛋白淀粉样变性治疗市场的当前和未来需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。转甲状腺素蛋白淀粉样变性治疗市场的主要参与者包括辉瑞公司、强生服务公司、Ionis Pharmaceuticals Inc.、Alnylam Pharmaceuticals Inc.、BridgeBio Pharma Inc.、百时美施贵宝公司、Acrotech Biopharma、阿斯利康、Prothena 、SOM生物技术。本节包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市场亮点
• 全球市场概况

第 3 章：转甲状腺素蛋白淀粉样变性治疗 - 行业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 行业动态
• 波特五力分析
• 市场吸引力分析
  • 按类型分類的市场吸引力分析
  • 按治疗方法进行的市场吸引力分析
  • 按疾病类型分類的市场吸引力分析
  • 按分销渠道分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原料厂商清单
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直效行销
  • 间接营销
  • 营销渠道发展趋势

第 5 章：COVID-19 爆发的影响分析

第 6 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按类型

• 按类型概述
• 历史和预测数据
• 按类型分析
• ATTR-PN
• ATTR-CM

第 7 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按治疗方法

• 治疗概述
• 历史和预测数据
• 治疗分析
• 标靶治疗（Onpattro、Inotersen、Vyndaqel/Vyndamax）
• 支持疗法
• 管道疗法

第 8 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按疾病类型

• 按疾病类型概述
• 历史和预测数据
• 按疾病类型分析
• 遗传性运甲状腺素蛋白淀粉样变性（多发性神经病、心肌病、混合型）
• 野生型淀粉样变性

第 9 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按分销渠道

• 按分销渠道分類的概览
• 历史和预测数据
• 按分销渠道分析
• 医院药房
• 专业药房
• 零售药店
• 网上药店

第 10 章：全球转甲状腺素蛋白淀粉样变性治疗市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概述、历史和预测销售分析
  • 北美按细分市场销售分析
  • 北美按国家/地区销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概述、历史和预测销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家/地区销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概述、历史和预测销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概述、历史和预测销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家/地区销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概述、历史和预测销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 11 章：转甲状腺素蛋白淀粉样变性治疗公司的竞争格局

• 运甲状腺素蛋白淀粉样变性治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 12 章：公司简介

• 顶级公司股票分析
• 市场集中度
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Johnson & Johnson Services Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Ionis Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Alnylam Pharmaceuticals Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• BridgeBio Pharma Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Bristol-Myers Squibb Company
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Acrotech Biopharma
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AstraZeneca
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Prothena
• 公司简介
• 公司收入
• 产品
• 最近的发展
• SOM Biotech
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

The global demand for Transthyretin Amyloidosis Treatment Market is presumed to reach the market size of nearly USD 14.73 BN by 2030 from USD 6.94 BN in 2022 with a CAGR of 8.72% under the study period 2023 - 2030.

Transthyretin amyloidosis treatment reduces amyloidosis and limits amyloid protein production. Transthyretin amyloidosis is a rare and life-threatening disease. This disease can affect multiple organs of a person with symptoms including loss of appetite, diarrhea, spinal stenosis, constipation, and many more. Transthyretin amyloidosis happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness.

MARKET DYNAMICS:

The presence of supportive reimbursement programs and the growing African-American population drive the transthyretin amyloidosis treatment market. Moreover, the increasing prevalence of disease and rising need for treatment options are anticipated to drive the market's growth soon. Also, the introduction of novel therapies is expected to boost the growth of the transthyretin amyloidosis treatment market. Furthermore, the major factors driving the global transthyretin amyloidosis treatment market are increased awareness, advancements in diagnostic procedures, improvement in healthcare services, rapid economic growth in developing countries, and increased research and development activity. However, low awareness and high cost of transthyretin amyloidosis treatment may hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of transthyretin amyloidosis treatment. The growth and trends of transthyretin amyloidosis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the transthyretin amyloidosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• ATTR-PN
• ATTR-CM

By Therapy

• Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
• Supportive Therapy
• Pipeline Therapy

By Disease Type

• Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
• Wild Type Amyloidosis

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Transthyretin Amyloidosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the transthyretin amyloidosis treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., BridgeBio Pharma Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Prothena, SOM Biotech. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . TRANSTHYRETIN AMYLOIDOSIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Therapy
  • 3.7.3 Market Attractiveness Analysis By Disease Type
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY TYPE

• 6.1 Overview by Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Type
• 6.4 ATTR-PN Historic and Forecast Sales by Regions
• 6.5 ATTR-CM Historic and Forecast Sales by Regions

7 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY THERAPY

• 7.1 Overview by Therapy
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Therapy
• 7.4 Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Historic and Forecast Sales by Regions
• 7.5 Supportive Therapy Historic and Forecast Sales by Regions
• 7.6 Pipeline Therapy Historic and Forecast Sales by Regions

8 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISEASE TYPE

• 8.1 Overview by Disease Type
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Disease Type
• 8.4 Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Historic and Forecast Sales by Regions
• 8.5 Wild Type Amyloidosis Historic and Forecast Sales by Regions

9 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 9.1 Overview by Distribution Channel
• 9.2 Historical and Forecast Data
• 9.3 Analysis by Distribution Channel
• 9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 9.5 Specialty Pharmacies Historic and Forecast Sales by Regions
• 9.6 Retail Pharmacies Historic and Forecast Sales by Regions
• 9.7 Online Pharmacies Historic and Forecast Sales by Regions

10 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE TRANSTHYRETIN AMYLOIDOSIS TREATMENT COMPANIES

• 11.1. Transthyretin Amyloidosis Treatment Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

• 12.1. Top Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Pfizer Inc.
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. Johnson & Johnson Services Inc.
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. Ionis Pharmaceuticals Inc.
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. Alnylam Pharmaceuticals Inc.
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. BridgeBio Pharma Inc.
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. Bristol-Myers Squibb Company
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. Acrotech Biopharma
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. AstraZeneca
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments
• 12.11. Prothena
  • 12.11.1. Company Overview
  • 12.11.2. Company Revenue
  • 12.11.3. Products
  • 12.11.4. Recent Developments
• 12.12. SOM Biotech
  • 12.12.1. Company Overview
  • 12.12.2. Company Revenue
  • 12.12.3. Products
  • 12.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Type (USD MN)
• ATTR-PN Market Sales by Geography (USD MN)
• ATTR-CM Market Sales by Geography (USD MN)
• Analysis Market by Therapy (USD MN)
• Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Market Sales by Geography (USD MN)
• Supportive Therapy Market Sales by Geography (USD MN)
• Pipeline Therapy Market Sales by Geography (USD MN)
• Analysis by Disease Type (USD MN)
• Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Market Sales by Geography (USD MN)
• Wild Type Amyloidosis Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Specialty Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Transthyretin Amyloidosis Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Transthyretin Amyloidosis Treatment Report
• Market Research Process
• Market Research Methodology
• Global Transthyretin Amyloidosis Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Type
• Market Attractiveness Analysis by Therapy
• Market Attractiveness Analysis by Disease Type
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Type (USD MN)
• ATTR-PN Market Sales by Geography (USD MN)
• ATTR-CM Market Sales by Geography (USD MN)
• Global Market Analysis by Therapy (USD MN)
• Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Market Sales by Geography (USD MN)
• Supportive Therapy Market Sales by Geography (USD MN)
• Pipeline Therapy Market Sales by Geography (USD MN)
• Global Market Analysis by Disease Type (USD MN)
• Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Market Sales by Geography (USD MN)
• Wild Type Amyloidosis Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Specialty Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.